• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non-Small-Cell Lung Cancer: Case Series.

作者信息

Gupta Ashish, Jatwani Karan, Gupta Kush, Qiu Jingxin, Dy Grace K

机构信息

Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY.

Department of Medicine, University of Massachusetts Medical School-Baystate, Springfield, MA.

出版信息

JCO Precis Oncol. 2023 Feb;7:e2200476. doi: 10.1200/PO.22.00476.

DOI:10.1200/PO.22.00476
PMID:36809053
Abstract
摘要

相似文献

1
Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non-Small-Cell Lung Cancer: Case Series.Rb1缺失与TP53基因缺失/HER2突变的非小细胞肺癌中曲妥珠单抗德鲁昔康获得性耐药的发生相关：病例系列
JCO Precis Oncol. 2023 Feb;7:e2200476. doi: 10.1200/PO.22.00476.
2
Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.病例报告：携带有 TP53 和 RB1 突变的 EGFR 突变型肺腺癌对 TKI 治疗产生耐药性。
Ann Palliat Med. 2021 Dec;10(12):12886-12893. doi: 10.21037/apm-21-2016.
3
Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.病例报告：TP53 和 RB1 的缺失可能通过表达神经内分泌标志物促进肺腺癌向小细胞肺癌的转化。
Front Endocrinol (Lausanne). 2022 Dec 13;13:1006480. doi: 10.3389/fendo.2022.1006480. eCollection 2022.
4
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.同时存在 RB1 和 TP53 改变的 EGFR 突变型肺癌具有组织学转化和临床结局不良的风险。
J Thorac Oncol. 2019 Oct;14(10):1784-1793. doi: 10.1016/j.jtho.2019.06.002. Epub 2019 Jun 19.
5
RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient.RB1缺失导致一名晚期非小细胞肺癌患者发生小细胞肺癌转化，作为对帕博利珠单抗的获得性耐药。
Lung Cancer. 2021 Jan;151:101-103. doi: 10.1016/j.lungcan.2020.11.016. Epub 2020 Nov 20.
6
Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.视网膜母细胞瘤突变预示晚期非小细胞肺癌不良预后。
Cancer Med. 2019 Apr;8(4):1459-1466. doi: 10.1002/cam4.2023. Epub 2019 Feb 17.
7
REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.REST失活以及ASCL1和POU3F4的共表达是RB1/TP53失活的肺腺癌完全转化为神经内分泌癌所必需的。
Am J Pathol. 2022 Jun;192(6):847-861. doi: 10.1016/j.ajpath.2022.03.007. Epub 2022 Mar 30.
8
Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss.电离辐射联合PARP1抑制剂可降低RB1/TP53缺失的前列腺癌的放射抗性。
Cancer Invest. 2021 May;39(5):423-434. doi: 10.1080/07357907.2021.1899200. Epub 2021 Mar 24.
9
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.RB1 和 TP53 共突变与膀胱癌对免疫检查点抑制剂反应的基因组生物标志物密切相关。
BMC Cancer. 2021 Apr 20;21(1):432. doi: 10.1186/s12885-021-08078-y.
10
Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer.曲妥珠单抗德鲁替康在HER2突变型非小细胞肺癌中显示出持久的活性。
Cancer. 2022 Mar 1;128(5):938. doi: 10.1002/cncr.34102.

引用本文的文献

1
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.多种ERBB2/ERBB3激活改变和共改变对实体瘤中HER2/3靶向治疗具有重要意义。
Cancer Res Commun. 2025 Apr 1;5(4):680-693. doi: 10.1158/2767-9764.CRC-24-0620.
2
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance.抗体药物偶联物在转移性乳腺癌中的最佳序贯策略：评估疗效和交叉耐药性。
Oncologist. 2024 Aug 5;29(8):e957-e966. doi: 10.1093/oncolo/oyae055.